Key Takeaway: PolyPid has provided a corporate update highlighting the FDA's acceptance of its D-PLEX180 NDA with a priority review status. The PDUFA goal date is now set for November 28, 2026, which is approximately one quarter earlier than previously expected. Additionally, the company has secured a commercialization partnership with Azurity Pharmaceuticals, achieving $30 million in upfront and near-term milestones.
Market Sentiment Analysis
POSITIVE FACTORS
FDA accepted D-PLEX180 NDA with priority review.
PDUFA goal date is set for November 28, 2026.
Partnership with Azurity Pharmaceuticals includes $30 million in milestones.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+50%
120-day peak, hindsight
Typical move
4.8%
average across 4 past catalysts
Lead asset
D-PLEX
Phase 3 · Surgical Site Infection
Full Press Release Details
FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance Exclusive U.S. and Canada Commercialization Partnership with Azurity Pharmaceuticals; $30 Million in Upfront and Near-Term Milestones Achieved
Frequently Asked Questions
What is the PDUFA goal date for D-PLEX180?
The PDUFA goal date for D-PLEX180 is November 28, 2026.
Who is PolyPid's commercialization partner?
PolyPid has partnered with Azurity Pharmaceuticals for commercialization.
What financial milestones has PolyPid achieved?
PolyPid has achieved $30 million in upfront and near-term milestones.